Faraha Ahmed, Syed Sufian Ahmad, M. Mumtaz Alam, M. Shaqiquzzaman, Abul Kalam Najmi, Mohammad Ahmed Khan
{"title":"阿格列汀在血糖控制方面进展的机制见解：翻译观点","authors":"Faraha Ahmed, Syed Sufian Ahmad, M. Mumtaz Alam, M. Shaqiquzzaman, Abul Kalam Najmi, Mohammad Ahmed Khan","doi":"10.1186/s43088-025-00601-5","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Alogliptin belongs to gliptin family of drugs that inhibits ubiquitous enzyme dipeptidyl peptidase-4 (DPP-4). Gliptins increase the life-span of incretin hormones that appear to benefit functioning of several organs via various signaling pathways.</p><h3>Main body</h3><p>Alogliptin is approved for treatment of type 2 diabetes mellitus (T2DM) in majority of the countries. It is administered orally and efficacious as monotherapy as well as combined therapy with other T2DM drugs, such as pioglitazone and metformin. It has a good safety profile, well-tolerated in elderly patients and in patients with co-morbid conditions including risks of cardiovascular event, renal or hepatic insufficiency. Therefore, alogliptin is incessantly experimented and investigated for its therapeutic benefit. Recent developments have indicated potential of alogliptin in discrete pathological conditions. Emerging evidences suggest prominent cardioprotective, hepatoprotective, reno-protective, anti-inflammatory and lipid-lowering capacity of alogliptin. Apart from inhibiting DPP-4 enzyme, alogliptin also affects several signaling mechanisms to exhibit protective effects in patients with diabetes-induced complications.</p><h3>Conclusion</h3><p>This review highlights the potential role of alogliptin and mechanisms involved in amelioration of several other pathological conditions apart from its role in glucose metabolism. Thus, this may provide insights for better utilization and repurposing of alogliptin as a therapeutic agent.</p></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"14 1","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjbas.springeropen.com/counter/pdf/10.1186/s43088-025-00601-5","citationCount":"0","resultStr":"{\"title\":\"Mechanistic insights toward progress in alogliptin beyond glycemic control: translational perspective\",\"authors\":\"Faraha Ahmed, Syed Sufian Ahmad, M. Mumtaz Alam, M. Shaqiquzzaman, Abul Kalam Najmi, Mohammad Ahmed Khan\",\"doi\":\"10.1186/s43088-025-00601-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Alogliptin belongs to gliptin family of drugs that inhibits ubiquitous enzyme dipeptidyl peptidase-4 (DPP-4). Gliptins increase the life-span of incretin hormones that appear to benefit functioning of several organs via various signaling pathways.</p><h3>Main body</h3><p>Alogliptin is approved for treatment of type 2 diabetes mellitus (T2DM) in majority of the countries. It is administered orally and efficacious as monotherapy as well as combined therapy with other T2DM drugs, such as pioglitazone and metformin. It has a good safety profile, well-tolerated in elderly patients and in patients with co-morbid conditions including risks of cardiovascular event, renal or hepatic insufficiency. Therefore, alogliptin is incessantly experimented and investigated for its therapeutic benefit. Recent developments have indicated potential of alogliptin in discrete pathological conditions. Emerging evidences suggest prominent cardioprotective, hepatoprotective, reno-protective, anti-inflammatory and lipid-lowering capacity of alogliptin. Apart from inhibiting DPP-4 enzyme, alogliptin also affects several signaling mechanisms to exhibit protective effects in patients with diabetes-induced complications.</p><h3>Conclusion</h3><p>This review highlights the potential role of alogliptin and mechanisms involved in amelioration of several other pathological conditions apart from its role in glucose metabolism. Thus, this may provide insights for better utilization and repurposing of alogliptin as a therapeutic agent.</p></div>\",\"PeriodicalId\":481,\"journal\":{\"name\":\"Beni-Suef University Journal of Basic and Applied Sciences\",\"volume\":\"14 1\",\"pages\":\"\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-02-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://bjbas.springeropen.com/counter/pdf/10.1186/s43088-025-00601-5\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Beni-Suef University Journal of Basic and Applied Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://link.springer.com/article/10.1186/s43088-025-00601-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MULTIDISCIPLINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Beni-Suef University Journal of Basic and Applied Sciences","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s43088-025-00601-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
Alogliptin belongs to gliptin family of drugs that inhibits ubiquitous enzyme dipeptidyl peptidase-4 (DPP-4). Gliptins increase the life-span of incretin hormones that appear to benefit functioning of several organs via various signaling pathways.
Main body
Alogliptin is approved for treatment of type 2 diabetes mellitus (T2DM) in majority of the countries. It is administered orally and efficacious as monotherapy as well as combined therapy with other T2DM drugs, such as pioglitazone and metformin. It has a good safety profile, well-tolerated in elderly patients and in patients with co-morbid conditions including risks of cardiovascular event, renal or hepatic insufficiency. Therefore, alogliptin is incessantly experimented and investigated for its therapeutic benefit. Recent developments have indicated potential of alogliptin in discrete pathological conditions. Emerging evidences suggest prominent cardioprotective, hepatoprotective, reno-protective, anti-inflammatory and lipid-lowering capacity of alogliptin. Apart from inhibiting DPP-4 enzyme, alogliptin also affects several signaling mechanisms to exhibit protective effects in patients with diabetes-induced complications.
Conclusion
This review highlights the potential role of alogliptin and mechanisms involved in amelioration of several other pathological conditions apart from its role in glucose metabolism. Thus, this may provide insights for better utilization and repurposing of alogliptin as a therapeutic agent.
期刊介绍：
Beni-Suef University Journal of Basic and Applied Sciences (BJBAS) is a peer-reviewed, open-access journal. This journal welcomes submissions of original research, literature reviews, and editorials in its respected fields of fundamental science, applied science (with a particular focus on the fields of applied nanotechnology and biotechnology), medical sciences, pharmaceutical sciences, and engineering. The multidisciplinary aspects of the journal encourage global collaboration between researchers in multiple fields and provide cross-disciplinary dissemination of findings.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
